Aurora Cannabis (TSX:ACB) Revenues Disrupt Cannabis Stocks

Aurora Cannabis Inc (TSX:ACB)(NYSE:ACB) expects to report an 81% increase in Q4 net revenues.

| More on:

Mark your calendars. Aurora Cannabis (TSX:ACB)(NYSE:ACB) will release official fourth-quarter earnings on September 15. The stock should bounce when the company announces record revenues.

On Tuesday, Aurora released preliminary estimates of quarterly net revenue above $100 million for the fourth quarter ended June 30. Fiscal year revenue estimates total over $250 million — a substantial increase from 2018.

Aurora tracks company performance based on gross margins, kilograms of cannabis sold, and cash costs per gram produced. Shareholders can expect the yearly report to highlight the data surrounding these measures. Preliminary cannabis production figures hint at annual sales of nearly 30,000 kg.

Although growth and investment remain the number one priority, Aurora will soon integrate positive adjusted EBITDA from cannabis operations into the company’s key performance goals. Last year, Aurora announced adjusted EBITDA of negative $205.82 million.

Aurora Cannabis

Aurora Cannabis is Canada’s top cannabis cultivator and distributor with an expansive business network throughout the European Union. To date, Aurora operates under 17 subsidiaries including Aurora Deutschland, MED Colombia, and Chemi Pharmaceutical.

Aurora’s expansive international reach and strategic partnerships distinguish it from its competitors. In fact, Aurora already has exclusive partnerships with pharmacies in Germany and the U.K. to sell medical marijuana by prescription.

Moreover, top cannabis innovators, such as Capcium, Evio Beauty Group, and Wagner Dimas, have partnered with Aurora to develop quality cannabis brands.

Capcium

Capcium is a market leader in softgel encapsulation of cannabis extracts, providing pharmaceutical-grade manufacturing to the cannabis industry. Aurora launched softgel capsules for both medical and adult-use cannabis markets at the end of 2018 under the CanniMed brand.

The softgel capsules contain equal proportions of CBD and THC in a six mg discrete pill format. The tablets are designed to balance the effects of CBD and THC and produce a long-lasting and enjoyable experience.

Evio Beauty

In partnership with Evio Beauty, Aurora Cannabis produces the cannabis skincare brand, Evio Skin. Products in the EvioSkin/Aurora Cannabis Collection include a hemp seed oil rejuvenating mask, hemp fibre wipes, and Omega 3-6-9 revitalizing serum. The partnership gives Aurora Cannabis access to high-end cosmetics consumers through popular Sephora retail outlets.

The skincare line also gives Aurora a brand-recognition advantage among female consumers who shop directly through EvioBeauty.com. Evio gives a mention to the Aurora Cannabis brand under every EvioSkin product listed on the website.

Wagner Dimas

Aurora Cannabis announced a partnership with Wagner Dimas in the summer of 2018. That summer marked Aurora Cannabis’s entrance into high-margin products.

The association granted Aurora Cannabis exclusive licence over Wagner’s “pre-roll” technology. Wagner Dimas developed ground-breaking technology to mass-produce pre-filled cannabis cigarettes. Pre-roll styles go beyond traditional cigarette-style rolls — cone-shaped and cigar-sized options are best sellers among California and Las Vegas adult-use consumers.

Foolish takeaway

Aurora Cannabis is a real winner on the Toronto Stock Exchange. The stock’s market value may be below that of Canopy Growth, but day trading in cannabis stocks has left many of the cannabis stocks mispriced.

Aurora Cannabis trades at 80% of Canopy Growth’s price, even though Aurora’s equity and net receivables are growing at a much faster rate. For these reasons, investors should consider investing in shares of Aurora Cannabis — a stock left severely neglected during the cannabis speculation-palooza.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Debra Ray has no position in any of the stocks mentioned.

More on Cannabis Stocks

Cannabis business and marijuana industry concept as the shadow of a dollar sign on a group of leaves
Cannabis Stocks

Should You Buy Canopy Growth Stock or Green Thumb Stock Today?

Let's dive into two cannabis giants, and which one may be the better pick for long-term investors.

Read more »

Farmer smiles near cannabis crop
Cannabis Stocks

Could Aurora Cannabis Stock Finally Recover by Year-End?

Down 99% from all-time highs, Aurora Cannabis stock is focused on improving profit margins and expanding sales of its medical…

Read more »

Farmer smiles near cannabis crop
Cannabis Stocks

Are Pot Stocks About to Surge Again? 

With pot stocks making big moves of late, many investors are now asking whether the cannabis sector is worth investing…

Read more »

Farmer smiles near cannabis crop
Cannabis Stocks

Can Pot Stocks Aurora Cannabis and Canopy Growth Bounce Back in Q4?

Down over 99% from all-time highs, Canadian pot stocks such as Aurora Cannabis and Canopy Growth remain high-risk bets.

Read more »

Worker tags plants at an industrial cannabis operation
Cannabis Stocks

Can Canopy Growth Stock Finally Recover in 2024?

Down 98% from all-time highs, Canopy Growth remains a high-risk investment in 2024 given its weak fundamentals.

Read more »

Tech Stocks

3 No-Brainer Stocks to Buy With $20 Right Now

These three stocks are easy buys for those who don't have all that much to spend, and want long-term growth…

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

Slow Burn: Is Aurora Cannabis Finally a Good Buy in June?

One of the benefits of choosing from some of the most beaten-down market segments like cannabis is that even a…

Read more »

Caution, careful
Cannabis Stocks

I Wouldn’t Touch This TSX Stock With a 60-Foot Pole

I wouldn't touch Canopy Growth Corp (TSX:WEED) stock with a 60-foot pole.

Read more »